Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention

There is growing awareness of the overlap between oncologic and cardiovascular (CV) diseases, including a wide range of CV effects of anticancer therapies. As novel anticancer therapeutics become available and cancer survival outcomes improve, the CV implications of cancer therapy become increasingl...

Full description

Saved in:
Bibliographic Details
Published in:Annual review of medicine 2018-01, Vol.69 (1), p.97-111
Main Authors: Narayan, Vivek, Ky, Bonnie
Format: Article
Language:English
Subjects:
Anthracyclines - adverse effects
Antineoplastic Agents - adverse effects
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Immunological - adverse effects
biomarkers
Cancer
Cancer Survivors
Cancer therapies
cardio-oncology
Cardiotoxicity
Cardiovascular disease
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Complications
Epidemiology
Health risks
heart failure
Heart Failure - epidemiology
Heart Failure - etiology
Heart Failure - prevention & control
Humans
Neoplasms - therapy
Oncology
Radiotherapy - adverse effects
Risk assessment
risk factors
Survival
survivorship
Toxicity
Trastuzumab - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is growing awareness of the overlap between oncologic and cardiovascular (CV) diseases, including a wide range of CV effects of anticancer therapies. As novel anticancer therapeutics become available and cancer survival outcomes improve, the CV implications of cancer therapy become increasingly important. In addition to outlining the CV effects of commonly used cancer therapies and their consequences for long-term survivorship, this review highlights the recent efforts to improve the risk prediction and prevention of CV toxicity through the evaluation of sensitive measures for early toxicity detection and the implementation of cardioprotective strategies.
ISSN:0066-4219
1545-326X
1545-326X
DOI:10.1146/annurev-med-041316-090622